Class: Selective vascular endothelial growth factor antagonist
- Injection, intravitreal 40 mg/mL
Binds to vascular endothelial growth factor A and placental growth factor, resulting in neovascularization and vascular permeability.
C max is 0.02 mcg/mL (0 to 0.054 mcg/mL). T max is 1 to 3 days.
Vd is 6 L.
Terminal elimination half-life is approximately 5 to 6 days.
Special PopulationsRenal Function Impairment
No differences between patients with renal impairment and healthy renal function.Hepatic Function Impairment
No studies have been conducted.
Indications and Usage
Treatment of neovascular (wet) age-related macular degeneration.
Active intraocular inflammation; hypersensitivity to any component of the product; ocular or periocular infection.
Dosage and AdministrationAdults
Intravitreal 2 mg (0.05 mL) every 4 wk for the first 12 wk, followed by 2 mg (0.05 mL) once every 8 wk.
- For ophthalmic intravitreal injection only.
- Withdraw all of the vial contents through the supplied filter needle attached to the supplied 1 mL syringe. Replace filter needle with the supplied 30-gauge × 1/2-inch needle for intravitreal injection.
- Expel contents until the plunger tip is aligned with the 0.05 mL mark on the syringe.
- Prior to the injection, give adequate anesthesia and broad-spectrum microbicide.
- Perform the intravitreal injection procedure under aseptic conditions, including use of sterile gloves, sterile drape, and a sterile eyelid speculum (or equivalent).
- Use each vial for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before aflibercept is administered to the other eye.
Store between 36° and 46°F. Do not freeze. Protect from light. Store in original carton until use. Discard any unused product.
None well documented.
Arterial thromboembolic events (2%).
Conjunctival hemorrhage (25%); eye pain (9%); cataract (7%); vitreous detachment, vitreous floaters (6%); increased IOP (5%); conjunctival hyperemia, corneal erosion (4%); detachment of the retinal pigment epithelium, foreign body sensation in eye, increased lacrimation, injection-site pain (3%); retinal pigment epithelium tear, vision blurred (2%); corneal edema, eyelid edema, injection-site hemorrhage (1%); endophthalmitis; retinal detachment.
Monitor IOP and for endophthalmitis immediately following the injection. Monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.
Category C .
Safety and efficacy not established.
Endophthalmitis and retinal detachments
May occur within 60 min of intravitreal injection.
Arterial thromboembolic events (eg, nonfatal MI, nonfatal stroke, vascular death) may occur.
No data available.
- Advise patient to seek immediate care from an ophthalmologist if the eye becomes red, sensitive to light, or painful, or if the patient develops a change in vision.
- Inform patients that they may experience a temporary visual disturbance after injection and the associated eye exams. Advise patients not to drive or use machinery until visual function has recovered sufficiently.
Copyright © 2009 Wolters Kluwer Health.
More Aflibercept resources
- Aflibercept Monograph (AHFS DI)
- aflibercept Injection Advanced Consumer (Micromedex) - Includes Dosage Information
- aflibercept MedFacts Consumer Leaflet (Wolters Kluwer)
- Zaltrap Prescribing Information (FDA)
- Zaltrap Advanced Consumer (Micromedex) - Includes Dosage Information
- Zaltrap Consumer Overview
- Zaltrap MedFacts Consumer Leaflet (Wolters Kluwer)